Previous 10 | Next 10 |
SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty (“Emerge”) to register and commercialize Adamis’ ...
SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that Dr. Ronald Moss, Chief Medical Officer, will be presenting data on October 4, 2019, pertaining to the company’s investigational high dose naloxone product candidat...
On August 28th, Adamis Pharmaceuticals ( ADMP ) updated investors on the U.S. launch of its SYMJEPI (0.3 mg) and SYMJEPI Jr. (0.15 mg) epinephrine injections. If you haven’t been following Adamis and the SYMJEPI saga, you should know that SYMJEPI 0.3 mg received FDA approval back in J...
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today the completion of pharmacokinetic (PK) studies comparing its naloxone injection product candidate, ZIMHI TM (naloxone) Injection, to a generic naloxone comparator. In June...
SAN DIEGO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPI TM (epinephrine) 0.3 mg and 0.15 mg Injections. During this back-to-school season, there is a heigh...
SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors. Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “We are very excited to bring...
Adamis Pharmaceuticals ( ADMP ) recently reported their Q2 earnings that revealed a slight miss on EPS and a miss on revenue. Typically, a miss on both EPS and revenue would have a negative impact on the stock. However, the company is starting to record substantial revenue growth quarter-over-...
SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application (U.S. Patent Application No. 15/914,804) des...
Adamis Pharmaceuticals Corporation (ADMP) Q2 2019 Results Conference Call August 08, 2019 05:00 PM ET Company Participants Dennis Carlo - President and Chief Executive Officer Rob Hopkins - Chief Financial Officer Ronald Moss - Chief Medical Officer David Marguglio - Chief Busi...
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2019 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuti...
News, Short Squeeze, Breakout and More Instantly...
Adamis Pharmaceuticals Corporation Company Name:
ADMP Stock Symbol:
NASDAQ Market:
Adamis Pharmaceuticals Corporation Website:
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing sm...
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 ...
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in...